1. SA Bradford, DL Marchette, AP Prezyna, CP Karakousis. Determining Breast, Melanoma and Ovarian Solid Tumor In Vitro Chemoresistance/Sensitivity While Simultaneously Characterizing The Tumor’s BioMorphoMolecular Marker (BMMM) Profile. A Preliminary Study. Accepted J Med. Sept, 2005.
  2. JM Hyatt, SA Mangione(Bradford), JJ Schentag. Flow Cytometric Analysis of Killing Streptococcus pneumoniae, Haemophilus influenza, and Staphylococcua aureus by Azrithrmoycin, Clarithromycin and Erythomycin in the Presence or Absence of Polymorphonuclear (PMN) Cells. Presented: 38th ICAAC, San Diego, CA, Sept, 1998.
  3. JM Hyatt, SA Mangione(Bradford), JJ Schentag. PD Modelling of Three Chemotherapeutic Agents and Human Lung Tumor Cells. Presented: Am Soc for Clin Pharm and Thera, San Antonio, TX, March, 1999.
  4. JM Hyatt, SA Mangione(Bradford), JJ Schentag. PD Modelling of Three Chemotherapeutic Agents and Human Lung Tumor Cells. Am Soc for Clin Pharm and Thera, San Antonio, 65: PIII-87, 1999.
  5. Britten RA; Evans AJ; Allalunis-Turner MJ; Franko AJ; Pearcey RG, Intratumoral heterogeneity as a confounding factor in clonogenic assays for tumour radioresponsiveness..Radiotherapy & Oncology. 39(2): 145-53, 1996
  6. Myatt N, Cree IA, Kurbacher CM, Foss AJE, Hungerford JL, Plowman PN. The ex vivo chemosensitivity profile of choroidal melanoma Anticancer Drugs. 8(8): 756-62, 1997.
  7. Cortazar P, Johnson BE: Review of the efficacy of individualized chemotherapy selected by in vitro sensitivity testing for patients with cancer.J Clin Oncology. 17(5): 1625-1631, 1999.
  8. Strauss E. Pretesting tumors Scientific Am. 19-22, 1999.
  9. Longman, R. “Becton Dickson bets that the Diagnostic game will be lost or won on novel content”, In Vivo: The Business report: 7-15, 1999.
  10. Sherry Bradford, PhD Inflammatory Breast Cancer, NBPW – Nike Magazine 2006
  11. Sherry Bradford, PhD Chemosensitivity and resistance in solid tumors. Roswell Park Cancer Institute Sept 15, 2008 WNY Medical Technology Association
  12. INVITED SPEAKER Bradford, Sherry, A. The use of Bio-active Markers to Compile a ‘Bio-score’ on which to Base a Chemoregimen in Patients with Ovarian Cancer. Traditional Cancer Therapy and Beyond in the New Millennium. Presented: Proceedings of the 6th Int’l Conf on Frontiers of Polymers and Adv Materials, Recife, Brazil, March, 2001.

Outside References

IN VITRO (OUTSIDE THE BODY) DRUG ASSAYS TRANSLATE INTO IN VIVO (INSIDE THE BODY) DRUG EFFICACY – REFERENCES

References:

  • Radiotherapy & Oncology. 39(2): 145-53, 1996.
  • Anticancer Drugs. 8(8): 756-62, 1997.
  • Anticancer Drugs. 8(6): 541-8, 1997.
  • Anticancer Drugs. 18(3A): 1633408, 1998.

References that state pretesting improves patient outcomes:

  • J Clin Oncology. 17(5): 1625-1631, 1999.
  • Scientific Am. 19-22, 1999.
  • Longman, R. “Becton Dickson bets that the Diagnostic game will be lost or won on novel content”, In Vivo: The Business report: 7-15, 1999.
  • Simonsen, M. “Growth is Forecast for tumor markers, oncogene assay market.” Am Health Consultants, 1(4): 1-6, 1998.

The Wall Street Journal
Tara Parker-Pope
Custom Chemo: Some Doctors Want it! – Sept. 14, 2004

Journal of Clinical Oncology, Vol 23, No 15 (May 20), 2005: pp. 3641-3643
© 2005 American Society of Clinical Oncology
DOI: 10.1200/JCO.2005.05.281

In Vitro Drug Resistance Versus Chemosensitivity: Two Sides of Different Coins John P. Fruehauf

  1. Survival outcomes in patients with recurrent ovarian cancer who
    Volume 189, Number 5. Am J Obstet Gynecol. Loizzi et al 1303 ….. PS tumors using assay-guided therapy compared with. women who were treated empirically.
    linkinghub.elsevier.com/retrieve/pii/S000293780300629X –
    Similar pages
    by V Loizzi – 2003 – Cited by 28Related articlesAll 4 versions
  2. International Journal of Gynecological Cancer – Fulltext: Volume
    Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided
    chemotherapy. Am J Obstet Gynecol 2003
    pt.wkhealth.com/pt/re/ijgc/fulltext.00009577-200705000-00008.htm –
    Similar pages
    by A SANTILLAN – 2007 – Cited by 2Related articles
  3. Survival outcomes in patients with recurrent ovarian cancer who
    File Format: PDF/Adobe Acrobat – View as HTML
    cancer who were treated with chemoresistance. assay-guided chemotherapy …. Volume 189, Number 5. Am J Obstet Gynecol. Loizzi et al 1303. Table II.
    www.medicorcancer.com/assets/chemofit/4doctors/Survival_Outcomes_Ovarian_Ca.pdf –
  4. Journals on the Web
    Konecny et al. provided evidence that stage III primary ovarian cancer patients ….. assay-guided chemotherapy. Am J Obstet Gynecol 2003, 189: 1301-7.
    journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_article_pr?p_JournalId=2&p_RefId=863394&p_IsPs=N&p_ispdf=N – Similar pages
    by U Testa – 2004 – Related articlesAll 3 versions